Brian Gallagher, a partner at SR One, will join SpringLeaf's board after the group invested in its B round.
SpringLeaf Therapeutics, a US-based technology platform for drug development formerly known as Entra Pharmaceuticals, has raised $15m in its series B round led by SR One, the corporate venturing unit of UK-listed healthcare firm GlaxoSmithKline.
Venture capital firms Flybridge Capital Partners and North Bridge Venture Partners reinvested in the B round having invested $12m in its A round in 2008.
Brian Gallagher, a partner at SR One, will join SpringLeaf’s board. He said: "SpringLeaf is developing a patient-centric platform to…
